Utilización de otros láseres en odontología: Argón, Nd:YAP y Ho:YAG

Las ventajas que la incorporación del láser ha proporcionado a la Odontología abarcan todos los ámbitos. Así, los láseres de Argón, de Nd:YAP y de Ho:YAG, tienen aplicaciones muy concretas y de gran interés tanto en el campo de la terapéutica dental como en la especialida de cirugía bucal. Las aplicaciones principales del láser de Argón se centran en la polimerización de los materiales de restauración, en la endodoncia y dentro del ámbito de la cirugía bucal, en el corte de tejidos blandos, principalmente para la exéresis de lesiones vasculares y pigmentadas. El láser de Nd:YAP se utiliza principalmente en el campo de la endodoncia y la periodoncia, y el láser de Ho:YAG se emplea en cirugía periapical y en la cirugía artroscópica de la articulación temporomandibular

Pilomatrixoma: review of 205 cases

Podeu consultar la versió en castellà del document a: http://hdl.handle.net/2445/153543Aims: To determine the incidence and clinical features of patients diagnosed with pilomatrixoma. Patients and Method: A retrospective analysis was made of 205 cases of pilomatrixoma diagnosed according to clinical and histological criteria, with an evaluation of the incidence, patient age at presentation, gender, lesion location and size, single or multiple presentation, differential diagnosis, histopathological and clinical findings and relapses. Results: Pilomatrixoma was seen to account for 1.04% of all benign skin lesions. It tended to present in pediatric patients- almost 50% corresponding to individuals under 20 years of age- with a slight male predilection (107/98). Approximately 75% of all cases presented as single lesions measuring less than 15 mm in diameter. Multiple presentations were seen in 2.43% of cases. The most frequent locations were the head and orofacial zones (particularly the parotid region), with over 50% of all cases, followed by the upper (23.9%) and lower limbs (12.7%). Only one relapse was documented following simple lesion excision. Conclusions: The frequency of pilomatrixomas was 1.04% of all benign skin lesions- the lesions being predominantly located in the maxillofacial area. Due to the benign features of this disorder, simple removal of the lesion is considered to be the treatment of choice, and is associated with a very low relapse rate

Pilomatrixoma: revisión de 205 casos

Podeu consultar la versió en anglès del document a: http://hdl.handle.net/2445/49003Objetivos: determinar la incidencia y las características clínicas de pacientes diagnosticados de pilomatrixoma. Pacientes y método: se realizó un análisis retrospectivo de 205 casos diagnosticados de pilomatrixoma según los criterios clínicos e histológicos, con una evaluación de la incidencia, la edad del paciente en el momento de presentar la lesión, sexo, localización y tamaño de la lesión, presentación única o múltiple, diagnóstico diferencial, histopatología, hallazgos clínicos e histopatológicos y recidivas. Resultados: el pilomatrixoma representa el 1.04% de todas las lesiones benignas de la piel. Suele presentarse en pacientes pediátricos- casi el 50% corresponde a personas menores de 20 años de edad- con una ligera predilección en hombres (107/98). Aproximadamente el 75% de todos los casos presentados eran lesiones individuales que median menos de 15 mm de diámetro. Se presentó de forma múltiple en el 2.43% de los casos. Las localizaciones más frecuentes fueron la cabeza y las regiones orofaciales (particularmente la región parotídea), con más de 50% de los casos, seguido de las extremidades superiores (23,9%) y las inferiores (12,7%). Sólo hubo una recidiva tras la escisión simple de la lesión. Conclusiones: la frecuencia de pilomatrixomas fue de 1,04% de todas las lesiones benignas de la piel - las lesiones se localizaron predominantemente en el área maxilofacial. Debido a las características de este trastorno benigno, la extirpación simple de la lesión se considera el tratamiento de elección, y se asocia con una tasa de recidiva muy baja

Pilomatrixoma: review of 205 cases

Aims: To determine the incidence and clinical features of patients diagnosed with pilomatrixoma. Patients and Method: A retrospective analysis was made of 205 cases of pilomatrixoma diagnosed according to clinical and histological criteria, with an evaluation of the incidence, patient age at presentation, gender, lesion location and size, single or multiple presentation, differential diagnosis, histopathological and clinical findings and relapses. Results: Pilomatrixoma was seen to account for 1.04% of all benign skin lesions. It tended to present in pediatric patients- almost 50% corresponding to individuals under 20 years of age- with a slight male predilection (107/98). Approximately 75% of all cases presented as single lesions measuring less than 15 mm in diameter. Multiple presentations were seen in 2.43% of cases. The most frequent locations were the head and orofacial zones (particularly the parotid region), with over 50% of all cases, followed by the upper (23.9%) and lower limbs (12.7%). Only one relapse was documented following simple lesion excision. Conclusions: The frequency of pilomatrixomas was 1.04% of all benign skin lesions- the lesions being predominantly located in the maxillofacial area. Due to the benign features of this disorder, simple removal of the lesion is considered to be the treatment of choice, and is associated with a very low relapse rate

Utilización de otros láseres en odontología: Argón, Nd:YAP y Ho:YAG

Las ventajas que la incorporación del láser ha proporcionado a la Odontología abarcan todos los ámbitos. Así, los láseres de Argón, de Nd:YAP y de Ho:YAG, tienen aplicaciones muy concretas y de gran interés tanto en el campo de la terapéutica dental como en la especialida de cirugía bucal. Las aplicaciones principales del láser de Argón se centran en la polimerización de los materiales de restauración, en la endodoncia y dentro del ámbito de la cirugía bucal, en el corte de tejidos blandos, principalmente para la exéresis de lesiones vasculares y pigmentadas. El láser de Nd:YAP se utiliza principalmente en el campo de la endodoncia y la periodoncia, y el láser de Ho:YAG se emplea en cirugía periapical y en la cirugía artroscópica de la articulación temporomandibular

Actualización en implantología bucofacial. Revisión de la literatura del año 2004. 2ª parte

Podeu consultar la primera part de l'article a http://hdl.handle.net/2445/163637Los autores revisan los artículos publicados en las revistas científicas más relevantes en el ámbito de la implantología bucofacial publicados durante el año 2004, destacando las novedades más significativas en cuanto a diseño y superficie de los implantes, carga inmediata, implantes inmediatos, técnicas especiales, implantes unitarios, elevación del suelo del seno maxilar, complicaciones y periimplantitis

Should high-dose-rate brachytherapy boost be used in early nasopharyngeal carcinomas?

BackgroundRadiation with or without chemotherapy is the main treatment of nasopharyngeal carcinomas (NPC). Local recurrence is difficult to manage. Local control is dose-dependent.AimTo analyze the effect of an endocavitary brachytherapy boost after external beam radiation (EBRT) to decrease local recurrence.Material and methodsThirty patients with T0-T2 NPC were treated: 70% T1, 20% T2 and 10% T0; 33.3% N0, 20% N1, 43.3% N2 and 3.3% N3; 90% were undifferentiated carcinoma. All they received a 192-Ir high dose rate brachytherapy (HDR-BT) boost after 60 Gy of EBRT. The Rotterdam applicator was used in most cases, 3-4 fractions of 3.75-3 Gy in two days.ResultsWith median follow-up (FU) of 63 months, a single parapharyngeal failure resulted in local control of 100% at 3 years and 95% at 5 years. Local control for T0-1 was 100% and for T2 67% at five years (p = 0.02). Regional-free recurrence survival was 92% at 5 years. Metastasis-free survival was 84% at 5 years. All cases of metastasis had histopathology of undifferentiated. The overall and cause-specific survival was 96% and 86% at 3 and 5 years. No late complications related to brachytherapy were described.ConclusionA HDR-BT boost is useful to decrease the incidence of local recurrence of NPC to 5%. With a fractionated schedule of 3-4 fractions in two days, Rotterdam applicator and 3-D planning, no late complications are described. Therefore we recommend to use brachytherapy boost in all early NPC

Bone marrow biopsy superiority over PET/CT in predicting progression-free survival in a homogeneously-treated cohort of diffuse large B-cell lymphoma.

Several studies have reported uneven results when evaluating the prognostic value of bone marrow biopsy (BMB) and PET/CT as part of the staging of diffuse large B-cell lymphoma (DLBCL). The heterogeneity of the inclusion criteria and not taking into account selection and collinearity biases in the analysis models might explain part of these discrepancies. To address this issue we have carried a retrospective multicenter study including 268 DLBCL patients with a BMB and a PET/CT available at diagnosis where we estimated both the prognosis impact and the diagnostic accuracy of each technique. Only patients treated with R-CHOP/21 as first line (n = 203) were included in the survival analysis. With a median follow-up of 25 months the estimated 3-year progression-free survival (PFS) and overall survival (OS) were 76.3% and 82.7% respectively. In a multivariate analysis designed to avoid a collinearity bias with IPI categories, BMB-BMI [bone marrow involvement](+) (HR: 3.6) and ECOG PS > 1 (HR: 2.9) were independently associated with a shorter PFS and three factors, age >60 years old (HR: 2.4), ECOG PS >1 (HR: 2.4), and abnormally elevated B2-microglobulin levels (HR: 2.2) were independently associated with a shorter OS. In our DLBCL cohort, treated with a uniform first-line chemotherapy regimen, BMI by BMB complemented performance status in predicting those patients with a higher risk for relapse or progression. In this cohort BMI by PET/CT could not independently predict a shorter PFS and/or OS